Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 1998

View Archived Issues

British Biotech: Q1 1998/99 highlights and shareholder update at AGM

New treatment option now available for type II diabetics in the U.K.

Creative BioMolecules modifies Biogen partnership

Aquila reports preliminary results of phase II trial of pneumococcal vaccine

Faulding Canada to promote ImmunoCyt in Canada

Taxol combination therapy approved in France for NSCLC indication

Endorex adds second site to phase II ImmTher trial

Novel anticancer agent from ProScript moves into clinical testing

Hemosol successfully completes U.K. Hemolink trial

Data safety monitoring board deems Nabi S. aureus vaccine safe in hemodialysis patients

New animal model of bone metastasis developed at AntiCancer

Vanguard Medica: six-month highlights

Scientists at Cell Therapeutics disclose new signal transduction inhibitors

Alcon licenses ciprofloxacin otic products from Bayer

Janssen product pipeline updated

Discovery of MRI contrast agents focus of Epix and NeoGenesis collaboration

E.U. approval granted for rabeprazole; product launched in U.K.

Patent protection for method of treating neurodegenerative disorders pioneered by NeoTherapeutics

Scripps uses DGT's gene expression technology to discover new treatments for HBV

Boston Scientific to copromote Targis System for BPH

Gene for Rx, Dx of liver cancer available for licensing from RCT

Alza now marketing MacroBID and Macrodantin in Canada

Orphan drug designation granted to MEDI-507 for use in AlloMune system

Vitrase to be fast-tracked by FDA

First FDA approval for once-daily use of an inhaled corticosteroid for asthma

Wayne Hughes Institute develops potent new agent for breast cancer

U.S. availability of new broad-spectrum cephalosporin antibiotic announced

Certiva vaccine launched in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...